Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study-Reference-Cited by-全球学者库

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

Published:2019-04 Issue:4 Volume:7 Page:347-357
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Leighl Natasha B,Hellmann Matthew D,Hui Rina,Carcereny Enric,Felip Enriqueta,Ahn Myung-Ju,Eder Joseph Paul,Balmanoukian Ani S,Aggarwal Charu,Horn Leora,Patnaik Amita,Gubens Matthew,Ramalingam Suresh S,Lubiniecki Gregory M,Zhang Jin,Piperdi Bilal,Garon Edward B

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference29 articles.

1. SEER Cancer Statistics Review, 1975-2015;Noone,2018

2. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer;Reck;Immunotherapy,2018

3. Factors associated with better overall survival in patients with previously treated, PD-L1–expressing, advanced NSCLC: multivariate analysis of KEYNOTE-010;Herbst,2017

4. Pembrolizumab for the treatment of non–small-cell lung cancer;Garon;N Engl J Med,2015

5. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer;Chatterjee;Ann Oncol,2016

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy;Journal of Biomedical Science;2024-01-29

2. Immunotherapy;Lung Cancer;2024

3. First-line therapy;Lung Cancer;2024

4. Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review;Frontiers in Oncology;2023-10-13

5. Progresses in biomarkers for cancer immunotherapy;MedComm;2023-10